Affordable Access

Targeting the non-coding genome and temozolomide signature enables CRISPR-mediated glioma oncolysis.

  • Tan, I-Li
  • Perez, Alexendar
  • Lew, Rachel
  • Sun, Xiaoyu
  • Baldwin, Alisha
  • Zhu, Yong
  • Shah, Mihir
  • Berger, Mitchel
  • Doudna, Jennifer
  • Fellmann, Christof
Publication Date
Nov 28, 2023
eScholarship - University of California
External links


Glioblastoma (GBM) is the most common lethal primary brain cancer in adults. Despite treatment regimens including surgical resection, radiotherapy, and temozolomide (TMZ) chemotherapy, growth of residual tumor leads to therapy resistance and death. At recurrence, a quarter to a third of all gliomas have hypermutated genomes, with mutational burdens orders of magnitude greater than in normal tissue. Here, we quantified the mutational landscape progression in a patients primary and recurrent GBM, and we uncovered Cas9-targetable repeat elements. We show that CRISPR-mediated targeting of highly repetitive loci enables rapid elimination of GBM cells, an approach we term genome shredding. Importantly, in the patients recurrent GBM, we identified unique repeat sequences with TMZ mutational signature and demonstrated that their CRISPR targeting enables cancer-specific cell ablation. Cancer shredding leverages the non-coding genome and therapy-induced mutational signatures for targeted GBM cell depletion and provides an innovative paradigm to develop treatments for hypermutated glioma.

Report this publication


Seen <100 times